Related Experiment Video
Updated: Oct 21, 2025

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
Published on: April 25, 2014
Programmatic challenges in managing multidrug-resistant tuberculosis in Malawi
Loveness Charlie1, Bibie Saidi2, Emnet Getachew3
1Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University; KNCV TB Foundation, Challenge TB Project, Blantyre, Malawi.
Malawi faces significant hurdles in managing multidrug-resistant tuberculosis (MDR-TB), including funding shortages and diagnostic delays. Addressing these programmatic challenges is crucial for improving treatment success rates and combating the MDR-TB crisis.
Area of Science:
- Public Health
- Infectious Diseases
- Tuberculosis Research
Background:
- Multidrug-resistant tuberculosis (MDR-TB) presents a critical public health challenge in Malawi.
- Increasing MDR-TB cases, declining treatment success, and high loss to follow-up rates indicate issues with the national Programmatic Management of Drug-Resistant Tuberculosis (PMDT).
Purpose of the Study:
- To explore the programmatic challenges encountered in managing MDR-TB within Malawi.
Main Methods:
- A non-systematic literature search was conducted using PubMed and Google Scholar with keywords such as "MDR-TB," "extensively drug-resistant TB," and "Malawi."
- Reviewed existing guidelines, gray literature, and data from the National TB Program (NTP).
Main Results:
- Key challenges identified include decreased funding, limited GeneXpert access, diagnostic delays, prolonged treatment durations, and inadequate personal protective equipment.
- Other significant issues are long culture turnaround times, failure to initiate all diagnosed patients on treatment, lack of alternative second-line drugs, and insufficient patient transport services.
Conclusions:
- Achieving a "TB-free Malawi" necessitates intensified efforts at all levels, including domestic resource mobilization for enhanced MDR-TB program performance.
- Continued financial support from developing partners is vital for Malawi to effectively manage the ongoing MDR-TB crisis.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Therapeutic Drug Monitoring: Affecting Factors
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

